Longeveron (LGVN) Net Income towards Common Stockholders (2020 - 2026)
Longeveron (LGVN) recorded quarterly Net Income towards Common Stockholders of -$4.8 million in Q1 2026, up 12.29% quarter-over-quarter from -$5.4 million in Q4 2025, and up 7.84% on a YoY basis from -$4.4 million in Q1 2025.
Longeveron (LGVN) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Longeveron's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$4.8 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 7.84% year-over-year to -$4.8 million; the TTM figure through Mar 2026 stood at -$22.5 million (up 12.73% YoY), while the FY2025 annual figure was -$22.7 million, up 7.79% from the prior year.
- Net Income towards Common Stockholders was -$4.8 million for Q1 2026 at Longeveron, up from -$5.4 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$3.4 million in Q1 2022 to a low of -$11.9 million in Q2 2024.
- Historically, Net Income towards Common Stockholders has averaged -$5.4 million across 5 years, with a median of -$5.0 million in 2025.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders slumped 111.54% in 2024, then jumped 57.8% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$4.5 million in 2022, then tumbled by 35.25% to -$6.0 million in 2023, then surged by 32.3% to -$4.1 million in 2024, then plunged by 33.4% to -$5.4 million in 2025, then rose by 12.29% to -$4.8 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$4.8 million (Q1 2026), -$5.4 million (Q4 2025), and -$7.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | -4.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.78 Mn |
| Dec 31, 2025 | -5.44 Mn |
| Sep 30, 2025 | -7.22 Mn |
| Jun 30, 2025 | -5.03 Mn |
| Mar 31, 2025 | -5.18 Mn |
| Dec 31, 2024 | -4.08 Mn |
| Sep 30, 2024 | -4.57 Mn |
| Jun 30, 2024 | -11.91 Mn |
| Mar 31, 2024 | -4.09 Mn |
| Dec 31, 2023 | -6.03 Mn |
| Sep 30, 2023 | -5.90 Mn |
| Jun 30, 2023 | -5.63 Mn |
| Mar 31, 2023 | -4.72 Mn |
| Dec 31, 2022 | -4.46 Mn |
| Sep 30, 2022 | -5.24 Mn |
| Jun 30, 2022 | -4.22 Mn |
| Mar 31, 2022 | -3.39 Mn |
| Dec 31, 2021 | -4.03 Mn |
| Sep 30, 2021 | -4.91 Mn |
| Jun 30, 2021 | -5.06 Mn |